NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis $0.92 -0.01 (-0.86%) Closing price 10/6/2026 03:59 PM EasternExtended Trading$0.91 -0.01 (-1.19%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Werewolf Therapeutics Stock (NASDAQ:HOWL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Werewolf Therapeutics alerts:Sign Up Key Stats Today's Range$0.91▼$0.9450-Day Range$0.35▼$1.0052-Week Range$0.27▼$2.13Volume278,151 shsAverage Volume692,905 shsMarket Capitalization$44.81 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments. Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins. Its pipeline has included engineered cytokine therapies such as WTX-124, an investigational systemic interleukin-2 therapy, and WTX-330, an investigational interleukin-12 therapy. These programs are being developed for potential use across a range of solid tumors and may be evaluated alone or in combination with other cancer treatments. Founded in 2017 and headquartered in the United States, Werewolf Therapeutics does not market approved commercial products and is focused primarily on research, clinical development and collaborations related to its immunotherapy platform. As a development-stage biotechnology company, its programs remain subject to clinical, regulatory and manufacturing requirements before they can potentially reach patients.AI Generated. May Contain Errors. Read More Werewolf Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreHOWL MarketRank™: Werewolf Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 561st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingWerewolf Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialWerewolf Therapeutics has a consensus price target of $4.00, representing about 333.8% upside from its current price of $0.92.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Werewolf Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Werewolf Therapeutics are expected to grow in the coming year, from ($0.89) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Werewolf Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.59% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 2.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Werewolf Therapeutics this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,303.00 in company stock.Percentage Held by Insiders23.60% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Werewolf Therapeutics' insider trading history. Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HOWL Stock News HeadlinesWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Recommendation of "Hold" from BrokeragesSeptember 30, 2026 | americanbankingnews.comComparing Werewolf Therapeutics (NASDAQ:HOWL) & Recursion Pharmaceuticals (NASDAQ:RXRX)September 28, 2026 | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)September 24, 2026 | globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)September 9, 2026 | globenewswire.comWerewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat CancersAugust 27, 2026 | tipranks.com1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding BoostAugust 26, 2026 | finance.yahoo.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)August 24, 2026 | globenewswire.comSee More Headlines HOWL Stock Analysis - Frequently Asked Questions How have HOWL shares performed this year? Werewolf Therapeutics' stock was trading at $0.6335 at the beginning of 2026. Since then, HOWL stock has increased by 45.5% and is now trading at $0.9220. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its quarterly earnings data on Friday, July, 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.36. The company earned $21 million during the quarter, compared to analyst estimates of $21 million. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $120 million in an IPO on Wednesday, April 28th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Werewolf Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings7/31/2026Today10/06/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HOWL's financial health is in the Green zone, according to TradeSmith. HOWL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HOWL CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees14Year Founded2017Price Target and Rating Average Price Target for Werewolf Therapeutics$4.00 High Price Target$7.00 Low Price Target$1.00 Potential Upside/Downside+333.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.82 million Net MarginsN/A Pretax Margin-164.82% Return on Equity-166.99% Return on Assets-59.88% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual Sales$1.88 million Price / Sales23.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.81Miscellaneous Outstanding Shares48,600,000Free Float37,130,000Market Cap$44.81 million OptionableOptionable Beta0.51 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:HOWL) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOWL Stock Alerts